Leaflet: information for the user
Olanzapina Stada 10 mg film-coated tablets EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Olanzapina Stada contains the active ingredient olanzapina. Olanzapina belongs to a group of medicines called antipsychotics and is indicated for the treatment of the following diseases:
Olanzapina Stada has shown to prevent the recurrence of these symptoms in patients with bipolar disorder whose manic episodes have responded to treatment with olanzapina.
Do not take Olanzapina Stada:
Warnings and precautions
Consult your doctor or pharmacist before starting to take Olanzapina Stada.
A weight gain has been observed in patients taking Olanzapina Stada. You and your doctor should check your weight regularly. If necessary, your doctor may help you plan a diet or refer you to a nutritionist.
If you have any of the following conditions, inform your doctor as soon as possible:
If you have dementia, you or your caregiver or family member should inform your doctor if you have ever had a stroke or transient ischemic attack.
As a routine precaution, if you are over 65 years old, it would be advisable for your doctor to monitor your blood pressure.
Children and adolescents
Patients under 18 years old should not take Olanzapina Stada.
Use of Olanzapina Stada with other medications
Only use other medications at the same time as Olanzapina Stada if your doctor authorizes it. You may feel drowsy if you combine Olanzapina Stada with antidepressants or medications for anxiety or sleep (tranquilizers).
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Specifically, tell your doctor if you are taking:
Use of Olanzapina Stada with alcohol
You should not drink alcohol if you have been administered Olanzapina Stada as it may cause drowsiness.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor before using this medication.
You should not take this medication while breastfeeding as small amounts of Olanzapina Stada may pass into breast milk.
The following symptoms may occur in newborns of mothers who used Olanzapina Stada in the last trimester (last three months of pregnancy): tremors, muscle stiffness, and/or weakness, drowsiness, agitation, respiratory problems, and difficulty feeding. If your baby experiences any of these symptoms, contact your doctor.
Driving and operating machinery
There is a risk of drowsiness when taking Olanzapina Stada. If this happens, do not drive vehicles or operate machinery. Consult your doctor.
Olanzapina Stada contains lactose and soy lecithin
This medication contains lactose. If your doctor has indicated that you have a certain sugar intolerance, consult with them before taking this medication.
This medication contains soy oil. Do not use it if you are allergic to peanuts or soy.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Your doctor will tell you how many tablets of Olanzapina Stada you should take and for how long. The daily dose of Olanzapina Stada ranges from 5 mg to 20 mg. Consult your doctor if you experience symptoms again, but do not stop taking Olanzapina Stada unless your doctor tells you to.
You should take your Olanzapina Stada tablets once a day, following your doctor's instructions. Try to take the tablets at the same time every day. You can take them with or without food. The coated tablets of Olanzapina Stada are for oral administration. You should swallow the Olanzapina Stada tablets whole with water.
If you take more Olanzapina Stada than you should
Consult your doctor, pharmacist, or call the Toxicological Information Service at telephone 91 562 04 20, indicating the medication and the amount used.
Patients who have taken more Olanzapina Stada than they should have experienced the following symptoms: rapid heartbeat, agitation/aggressiveness, speech problems, unusual movements (especially of the face and tongue) and a reduced level of consciousness. Other symptoms may include: acute confusion, seizures (epilepsy), coma, a combination of fever, rapid breathing, sweating, muscle rigidity, drowsiness or lethargy, slowed respiratory frequency, aspiration, increased blood pressure or decreased blood pressure, abnormal heart rhythms. Contact your doctor or go to the hospital immediately if you notice any of the mentioned symptoms. Show the doctor the packaging with the tablets.
If you forget to take Olanzapina Stada
Take your tablets as soon as you remember. Do not take a double dose to make up for the missed dose.
If you interrupt treatment with Olanzapina Stada
Do not stop treatment simply because you feel better. It is very important that you continue taking Olanzapina Stada as long as your doctor tells you to.
If you stop taking Olanzapina Stada suddenly, you may experience symptoms such as sweating, inability to sleep, tremors, anxiety, nausea, and vomiting. Your doctor may suggest that you gradually reduce the dose before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Immediately contact your doctor if you have:
Frequent side effects (can affect more than 1 in 10 people) include weight gain, drowsiness, and increased blood prolactin levels. In the early stages of treatment, some people may feel dizzy or faint (especially with slower heartbeats), especially when getting up from lying down or sitting. This sensation usually disappears spontaneously, but if it does not, consult your doctor.
Common side effects (can affect up to 1 in 10 people) include changes in the levels of some circulating blood cells and lipids and at the beginning of treatment, temporary increases in liver enzymes, increased blood sugar and urine levels, increased blood uric acid and creatine phosphokinase levels, increased appetite, dizziness, agitation, tremors, strange movements (dyskinesia), constipation, dry mouth, skin rash, loss of strength, excessive fatigue, fluid retention causing inflammation of the hands, ankles, or feet, fever, joint pain, and sexual dysfunction such as decreased libido in men and women or erectile dysfunction in men.
Rare side effects (can affect up to 1 in 100 people) include hypersensitivity (e.g., inflammation of the mouth and throat, itching, skin rash), diabetes or worsening of diabetes, occasionally related to ketoacidosis (acetone in blood and urine) or coma, seizures, in most cases related to a history of seizures (epilepsy), muscle stiffness or spasms (including eye movements), restless legs syndrome, speech problems, slow pulse, sensitivity to sunlight, nasal bleeding, abdominal distension, excessive salivation,memory loss or forgetfulness, urinary incontinence, loss of ability to urinate, hair loss, absence or decrease of menstrual periods, and changes in the breast gland in men and women such as abnormal milk production or abnormal growth.
Rare side effects (can affect up to 1 in 1,000 people) include a decrease in normal body temperature, abnormal heart rhythm, sudden unexplained death, pancreatitis, which causes severe stomach pain, fever, and discomfort, liver disease, with yellowing of the skin and white areas of the eye, muscle disorder presenting as unexplained pain, and prolonged and/or painful erection.
Very rare side effects include severe allergic reactions such as drug-induced eosinophilia and systemic symptoms (DRESS by its English acronym). Initially, DRESS manifests with symptoms similar to the flu with a rash on the face and later, with extensive rash, fever, swollen lymph nodes, elevated liver enzymes observed in blood tests, and increased levels of a type of white blood cell (eosinophilia).
During treatment with olanzapine, elderly patients with dementia may experience stroke, pneumonia, urinary incontinence, falls, extreme fatigue, visual hallucinations, increased body temperature, skin redness, and walking difficulties. Some deaths have been reported in this particular group of patients.
Olanzapine Stada may worsen symptoms in patients with Parkinson's disease.
Reporting of side effects
If you experience any type of side effect, consult your doctor or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: http://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging, after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required. Store in the original packaging.
Medications should not be disposed of through drains or in the trash. Deposit the containers and medications you no longer need at the SIGRE collection point of the pharmacy. Ask your pharmacist how to dispose of the containers and medications you no longer need. This way, you will help protect the environment.
Composition of Olanzapina STADA
Appearance of the product and content of the packaging
Olanzapina STADA 10 mg is presented in the form of film-coated tablets. The tablets are round, white, with the inscription “10” on one face.
It is presented in packaging of 28 or 56 tablets.
Holder of the marketing authorization and responsible for manufacturing:
Holder of the marketing authorization:
STADA Laboratory, S.L. Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Responsible for manufacturing:
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona, 69
08970 Sant Joan Despí (Barcelona)
Spain
Last review date of this prospectus:April 2020
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.